Pirarubicin clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How each study uses pirarubicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Pirarubicin
- 3
Studies by the year they started
6 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2010 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 6
Peking University First Hospital (2) · Tianjin Medical University Cancer Institute and Hospital (1) · RenJi Hospital (1) · Second Military Medical University (1) · Japan Adult Leukemia Study Group (1)
Often tested with
Tested in the same studies.
Dexamethasone (2) · Apatinib (1) · Ifosfamide (1) · Bortezomib (1) · Thalidomide (1) · Methotrexate (1) · Prednisolone (1) · Vincristine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Pirarubicin is the comparator. A study of two new drugs counts under both.
- 1Efserakefusp alfa · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Jun 2030
- 1Dulpatatug · Shanghai Henlius Biotech · next primary completion Jan 2028
Studies
Open first, then newest update. How each study uses pirarubicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue SarcomaStatus unknownPhase 2Tianjin Medical University Cancer Institute and HospitalNCT04126811Written as Apatinib Mesylate, Pirarubicin, Ifosfamide
- Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial CarcinomaStatus unknownPhase 2RenJi HospitalNCT03030157Written as pirarubicin(THP)
- Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma PatientsStatus unknownPhase 2Peking University First HospitalNCT02740426Written as Pirarubicin
- Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma PatientsStatus unknownPhase 2Peking University First HospitalNCT02923557Written as Pirarubicin
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaStatus unknownPhase 4Second Military Medical UniversityNCT01249690Written as Bortezomib,Pirarubicin,Dexamethasone
- Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)Status unknownPhase 2Japan Adult Leukemia Study GroupNCT00131053Written as Pirarubicin
Given beside what is tested · 7 — pirarubicin is usual care or a partner of the new treatment
- A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCRecruitingPhase 1Xijing HospitalNCT07178171Written as Pirarubicin
- Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingPhase 2Peking University People's HospitalNCT06714383Written as Pirarubicin
- Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNot yet recruitingNot applicableChinese Academy of Medical SciencesNCT05287308Written as pirarubicin
- Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular CarcinomaWithdrawnPhase 2/3Guangxi Medical UniversityNCT02585479Written as Pirarubicin
- CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell LymphomaStatus unknownPhase 4Ruijin HospitalNCT01746992Written as pirarubicin 50mg/m2
- Combine TACE and RFA Versus TACE Alone for HCC With PVTTStatus unknownPhase 3Ming ZhaoNCT02301091Written as pirarubicin,mitomycin and lobaplatin
- Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast CancerCompletedPhase 3307 Hospital of PLANCT02613026Written as Pirarubicin
As the comparator · 6 — what is tested is compared with pirarubicin
- A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast CancerNot yet recruitingNot applicablePeking University People's HospitalNCT07844291Written as THP
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07424287Written as Pirarubicin Hydrochloride for Injection
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07294508Written as THP
- Combination Therapy of Anthracyclines for Children With NephroblastomaNot yet recruitingPhase 4Shengjing HospitalNCT03892330Written as Pirarubicin
- Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast CancerStatus unknownPhase 4Hebei Medical University Fourth HospitalNCT02903524Written as pirarubicin and cyclophosphamide
- Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular CarcinomaStatus unknownPhase 3Sun Yat-sen UniversityNCT02755311Written as epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil
Codes
What other systems call pirarubicin · ClinicalTrials.gg INT002853
- MeSH (NLM) C027260pirarubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) D58G680W0GPIRARUBICINConfirmed FDA, NLM, Wikidata
- RxNorm 33764One source FDA
- Wikidata Q76416926pirarubicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1197PirarubicinOne source FDA
- DrugBank DB11616One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C027260 | pirarubicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | D58G680W0G | PIRARUBICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 33764 | — | One source FDA |
| Wikidata | Q76416926 | pirarubicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1197 | Pirarubicin | One source FDA |
| DrugBank | DB11616 | — | One source Wikidata |
Also registered as pirarubicin hydrochloride (UNII E7V83174BE).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.